Biogen Stock News

Overview: Recombinant DNA technology involves joining of two DNA molecules from two different species. It allows transfer of preferred specific characteristics, which helps to improve pre-existing systems and controls expression of target genes. Mass production of therapeutic proteins characterized by higher

Capital Investment Advisors LLC reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 15.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,616 shares of the biotechnology company’s stock after selling 484 shares during the period. Capital Investment Advisors LLC’s holdings in Biogen were worth $740,000 at the end of the most recent […]

Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players

Global Tumor Necrosis Factor Inhibitor Drugs Market - Snapshot New product releases, a strong pipeline, an increase in the prevalence of autoimmune illnesses, and a large increase in consumer knowledge of tumor necrosis factor (TNF) are likely to fuel growth of

Safety concerns are growing over Biogen’s Alzheimer’s drug Aduhelm as a new paper showed brain swelling in 35% of clinical trial patients.

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Related Stocks: ABBV , CDNS , SYK , ALL , BIIB , VNQ , BA , ALLE ,

Guardian Investment Management decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 4.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,165 shares of the biotechnology companys stock after selling 500 shares during the period. Biogen makes up about 2.1% of Guardian []

Biogen (NASDAQ:BIIB) had its price target decreased by Royal Bank of Canada from $295.00 to $277.00 in a research report report published on Friday, Price Targets.com reports. Royal Bank of Canada currently has a sector perform rating on the biotechnology companys stock. A number of other equities analysts have also weighed in on BIIB. Robert []

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen Inc. (NASDAQ:BIIB) Investment analysts at William Blair upped their FY2021 earnings per share estimates for shares of Biogen in a research report issued on Tuesday, November 16th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of $18.95 per share for the year, up from their prior estimate []

Global Idiopathic Pulmonary Fibrosis Treatment Market: Snapshot The idiopathic pulmonary fibrosis (IPF) treatment market has been experiencing tremendous growth opportunities across the world. This market growth is attributed to the increasing number of lung diseases among different countries across the globe.

Analysts at BMO Capital Markets began coverage on shares of Biogen (NASDAQ:BIIB) in a report released on Thursday, The Fly reports. The firm set an outperform rating on the biotechnology companys stock. Other analysts have also issued research reports about the company. Bank of America cut their price objective on Biogen from $400.00 to $360.00 []

Are we in for another winter surge? Has Biogen bottomed out? And can Covid-19 pills change the course of the pandemic? All that and more on the latest episode of…